Canadian Cancer Trials Group Bulletins

Trial Management Group

Trials Closed to Accrual

Canadian Cancer Trials Group MAC.4 / IBCSG 24-02-SOFT -- A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women With Endocrine Responsive Breast Cancer -- and MAC.4C / IBCSG ANZ 0701-Co-SOFT -- Investigating Cognitive Function for Patients Participating in the SOFT Trial in Selected Centres -- have closed to North American accrual as of 30 April 2010 as they were nearing their accrual goal. Select sites outside of North America will continue to accrue.

EORTC 62012 / Canadian Cancer Trials Group SR.5 -- Randomized Trial of Single Agent Doxorubicin Vs. Doxorubicin plus Ifosfamide in First-Line Treatment of Advanced or Metastatic Soft Tissue Sarcoma -- was officially closed to further accrual on 11 May 2010.